文献速递骨软组织肉瘤与黑色素瘤

阿替利珠单抗治疗腺泡状软组织肉瘤的临床试验更新

Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update.
PubMed 文献 · J Clin Oncol · 2026-04-18

这项关键II期试验更新了阿替利珠单抗治疗腺泡状软组织肉瘤(ASPS)的长期随访结果。53例患者中,中位缓解持续时间延长至37.0个月,客观缓解率(ORR)为35.8%(95%CI 23.1-50.2),中位无进展生存期(mPFS)为20.8个月(IQR 7.6-未达到)。ASPSCR1::TFE3融合1型患者的ORR和mPFS优于2型。长期结果支持阿替利珠单抗治疗ASPS,部分患者可考虑药物假期。

要点

  • 阿替利珠单抗治疗ASPS的ORR为35.8%,mPFS为20.8个月
  • 融合1型患者ORR 43.9%、mPFS 28.3个月,优于2型的0%和7.5个月
  • 长期用药后经密切监测可考虑药物假期

核心结论

  • 长期随访结果支持阿替利珠单抗用于治疗ASPS,甚至可持续数年。
  • 对部分患者,在密切监测下药物假期可能是一种选择。

研究设计与样本

  • 关键II期临床试验(NCT03141684)的更新分析,纳入53例接受阿替利珠单抗治疗的ASPS患者。
  • 本次报告增加了3年观察数据。

主要发现

  • 中位缓解持续时间延长至37.0个月。
  • 客观缓解率(ORR)为35.8%(95%CI 23.1-50.2),中位无进展生存期(mPFS)为20.8个月(IQR 7.6-未达到),与既往报告基本一致。
  • 47/53例患者确定了ASPSCR1::TFE3融合类型;表达1型的41例患者ORR为43.9%(95%CI 28.5-60.2),mPFS为28.3个月(IQR 9.2-未达到);表达2型的6例患者ORR为0%(95%CI 0-45.9),mPFS为7.5个月(IQR 3.9-未达到);PFS风险比为3.2(95%CI 1.01-10.2)。
  • 9例符合条件的患者在单药治疗进展后接受贝伐珠单抗联合阿替利珠单抗治疗,该小队列ORR为0%,mPFS为18.5个月(IQR 7.9-21.1)。

临床怎么用

  • 阿替利珠单抗可作为ASPS的长期治疗选择,疗效持久。
  • 治疗≥2年后,经密切监测可考虑个体化药物假期。
  • ASPSCR1::TFE3融合1型患者可能从阿替利珠单抗治疗中获益更多。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We previously reported initial results of the pivotal phase II trial of atezolizumab for patients with alveolar soft part sarcoma (ASPS; ClinicalTrials.gov identifier: NCT03141684). Here, we report on three additional years of observation. Fifty-three patients with ASPS received atezolizumab. Median duration of response increased to 37.0 months. Objective response rate (ORR) and median progression-free survival (mPFS) remained essentially as previously reported (35.8% [95% CI, 23.1 to 50.2] and 20.8 months [IQR, 7.6-not reached], respectively). ASPSCR1::TFE3 fusion type was determined for 47/53 patients; ORR and mPFS were higher among the 41 patients expressing type 1 (43.9% [95% CI, 28.5 to 60.2] and 28.3 months [IQR, 9.2-not reached], respectively) than the six patients expressing type 2 (0% [95% CI, 0 to 45.9] and 7.5 months [IQR, 3.9-not reached], respectively, PFS HR, 3.2 [95% CI, 1.01 to 10.2]). Eleven patients chose a per-protocol drug holiday (range, 3.5-26.4 months) after ≥2 years of treatment; two experienced disease progression during the holiday. Nine eligible patients elected to receive bevacizumab plus atezolizumab after progressing on monotherapy; ORR was 0% and mPFS was 18.5 months (IQR, 7.9-21.1) in this small cohort. Long-term results support using atezolizumab to treat ASPS, even for several years; a drug holiday with careful monitoring may be an option for some patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Chen AP, Rosenberger CL, Moore N, et al. Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update. J Clin Oncol. 2026. PMID: 41999612. doi:10.1200/JCO-25-02811

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。